These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children. Lykavieris P; Ducot B; Lachaux A; Dabadie A; Broué P; Sarles J; Bernard O; Jacquemin E J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):623-9. PubMed ID: 18955864 [TBL] [Abstract][Full Text] [Related]
8. Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis. Deneau MR; Mack C; Abdou R; Amin M; Amir A; Auth M; Bazerbachi F; Marie Broderick A; Chan A; DiGuglielmo M; El-Matary W; El-Youssef M; Ferrari F; Furuya KN; Gottrand F; Gupta N; Homan M; Jensen MK; Kamath BM; Mo Kim K; Kolho KL; Konidari A; Koot B; Iorio R; Martinez M; Mohan P; Palle S; Papadopoulou A; Ricciuto A; Saubermann L; Sathya P; Shteyer E; Smolka V; Tanaka A; Valentino PL; Varier R; Venkat V; Vitola B; Vos MB; Woynarowski M; Yap J; Miloh T Hepatol Commun; 2018 Nov; 2(11):1369-1378. PubMed ID: 30411083 [TBL] [Abstract][Full Text] [Related]
9. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. Deneau MR; El-Matary W; Valentino PL; Abdou R; Alqoaer K; Amin M; Amir AZ; Auth M; Bazerbachi F; Broderick A; Chan A; Cotter J; Doan S; El-Youssef M; Ferrari F; Furuya KN; Gottrand M; Gottrand F; Gupta N; Homan M; Kamath BM; Kim KM; Kolho KL; Konidari A; Koot B; Iorio R; Ledder O; Mack C; Martinez M; Miloh T; Mohan P; O'Cathain N; Papadopoulou A; Ricciuto A; Saubermann L; Sathya P; Shteyer E; Smolka V; Tanaka A; Varier R; Venkat V; Vitola B; Vos MB; Woynarowski M; Yap J; Jensen MK Hepatology; 2017 Aug; 66(2):518-527. PubMed ID: 28390159 [TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988 [TBL] [Abstract][Full Text] [Related]
11. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717 [TBL] [Abstract][Full Text] [Related]
12. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223 [TBL] [Abstract][Full Text] [Related]
13. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC. Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287 [TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Beuers U; Spengler U; Kruis W; Aydemir U; Wiebecke B; Heldwein W; Weinzierl M; Pape GR; Sauerbruch T; Paumgartner G Hepatology; 1992 Sep; 16(3):707-14. PubMed ID: 1505913 [TBL] [Abstract][Full Text] [Related]
15. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727 [TBL] [Abstract][Full Text] [Related]
16. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study. Rahimpour S; Nasiri-Toosi M; Khalili H; Ebrahimi-Daryani N; Nouri-Taromlou MK; Azizi Z J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301 [TBL] [Abstract][Full Text] [Related]
17. Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture. Fracchia M; Soubrane O; Houssin D; Galatola G Ital J Gastroenterol; 1995; 27(8):430-5. PubMed ID: 8775469 [TBL] [Abstract][Full Text] [Related]
18. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231 [TBL] [Abstract][Full Text] [Related]
19. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Lindor KD N Engl J Med; 1997 Mar; 336(10):691-5. PubMed ID: 9041099 [TBL] [Abstract][Full Text] [Related]
20. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]